Co-therapy of an anti-obesity agent, a statin, and a glitazone is disclosed along with fixed combinations thereof. Atorvastatin, rosiglitazone, and orlistat are preferred as the various components. Non-glitazone antidiabetic agents may be optionally added to the therapy and/or to the fixed combination product.

 
Web www.patentalert.com

< HYDROXYBENZOATE SALTS OF METANICOTINE COMPOUNDS

> METHOD FOR ACTIVATING THE LIPID CATABOLIC METABOLISM IN ENTERIC EPITHELIUM AND IMPROVING THE LIPID METABOLISM IN ENTERIC EPITHELIUM

~ 00467